 Hi, I'm Chris Thompson for Investor Intel and today I'm here with Brent Willis, the CEO of Voyager Pharmaceuticals, ticker VM on the TSX Ventures Exchange. How are you doing today, Brent? Doing great. Thanks for having me on. You've had a very busy year so far this year. Lots of news and product releases with your company. I think the first and foremost, we should talk about your recent financing, which you have just closed. Yeah, we had great success on our financing. We closed just over 1.5 million. We're all ready to move forward using those funds to advance our company. It's been a really great start. What are you primarily going to use those funds for over the next year? Well, we have allocated for several things. Most importantly, is our product rollouts, getting our products to market. The second is our preliminary economic assessment on our Francis Creek project, which is the main ingredient for barium sulfate contrast that we're putting to market. Those are our main two focuses right now. So maybe let's dive deep into the product then. What product are you bringing to market? Our first product we're going to bring to market is called SmoothX. So these products are used in X-rays and CT scans. We've identified the market in the United States for CT abdominal scans for rail contrasts, roughly around $188 million. So our first product going to market is going to be penetrating that market and we call that our SmoothX brand. So that's our main focus right now. We just started working with the FDA as of June 1st. They changed the designation for barium sulfate from a device or from a drug to a device and that has changed our budget constraints and has allowed us to free up more cash other places. And once we get the FDA device applications completed, we're looking at penetrating the US markets in early next year or mid next year. Now you have at least five different products and what are these products primarily used for? Each product has a specific market it's used in and it's all related to scanning from your throat all the way to the other end of your body. So it's your stomach, your upper and lower gastrointestinal tract. They do dysphagia swallows on X-rays. So there's multiple different markets for our products. They're used to contrast against your organs to determine whether you have a tumor or any other types of issues that's going on within your body. So it's a growing market and we believe that we're going to be coming out with products that are more competitive and more advanced than what's currently on the market. So let's touch on that then. So what is currently in the market and how do your products are more advantageous and I guess that maybe perhaps meeting a demand out there? Well we have the one we have the only natural barium sulfate deposit that makes great for pharmaceuticals outside of China. So all our other competitors are using synthetically man-made barium sulfate which is much more expensive. But it also allows us to tweak our particle size distribution and a little few things with our formulations to allow us to create our products to match up with the advancement in the CT market for example where our competitors haven't done any advancement over the last 20 years. So we have identified a lot of opportunity for us to move forward and create better products in a marketplace that globally is really controlled by one company. And geographically where is this source located? It's in British Columbia Canada and it sits right off side of a road. It's got all the infrastructure in place. It's been drilled and is an I-43 one on compliant and we're moving forward with a preliminary economic assessment on it and from there we will build out our quarry and our production facility. With the the Health Canada approvals how are you going to transition from being you know into a manufacturing company? Well we look at it as we're a pharmaceutical company that has our own source of feedstock for our products. So we're focused on barium contrast and iodine contrast and we know that we can fully integrate both spaces. We're starting with our barium sulfate so we have no middleman in the supply chain. We are direct from the earth to the bottle is what we are slogan and I think that really defines the whole concept of our business plan because we're looking at coming to market with the lowest reading costs in the market. And when do you think you'll see some revenue hit the bottom line? Our goal is Q1 of next year. Obviously we'll try to get that done earlier but to be conservative Q1 of 2022. And have you mentioned international expansion with getting FDA approval in the United States? Are you going after other international markets? Yeah we have interest from all over the world. We've been receiving phone calls since we've had our Health Canada approvals announced and we're talking to several distribution companies in countries all over the world. Everybody is looking for a second option, a new supply chain that will help diversify their businesses. That's great. So what can investors look forward to for the rest of the year from you? Well it's an exciting year for us. We obviously the product rollout as that moves forward. We're going to have some announcements on that pending contracts. Obviously we'll be coming down the pipeline. Our PEA which we expect will be completed come September is our goal. And once we have that then we're going to be looking at building our facilities and putting this whole project in full production. That's great. Thank you for your time today. This has been Chris Thompson speaking with Brett Willis CEO of Voyager Pharmaceuticals. Take care. It is a VM on the TSX Venture Exchange. Have a great day. Thank you.